| Business Summary | | Incara
Pharmaceuticals
Corporation
develops
innovative
pharmaceutical
products
and
treatments
for
major
diseases
afflicting
large
patient
populations.
The
Company
is
currently
developing
a
diversified
portfolio
of
three
potentially
breakthrough
treatments.
Each
of
these
products
targets
a
medical
disorder
for
which
there
are
no
fully
effective
treatments.
These
three
products
are
as
follows:
OP2000,
an
ultra-low
molecular
weight
heparin;
liver
precursor
cell
transplant,
as
a
treatment
for
liver
failure;
and
small
molecule
catalytic
antioxidants,
as
a
treatment
for
stroke
and
heart
attack.
The
Company
generally
plans
to
enter
into
relationships
with
companies
that
have
manufacturing,
sales
or
marketing
capabilities
to
bring
its
products
to
market. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Incara
pharmaceuticals
is
engaged
in
development
of
pharmaceutical
products
for
treatment
of:
inflammatory
bowel
disease,
liver
disorders
and
novel
small
molecule
antioxidants
for
disorders
such
as
stroke,
asthma
and
reperfusion
injury.
For
the
nine
months
ended
6/30/01,
revenues
fell
82%
to
$18
thousand.
Net
loss
applicable
to
Common
totaled
$13.1
million,
up
from
$4.5
million.
Results
reflect
the
absence
of
contract
revenues
and
the
recognition
of
a
$6
million
loss
incurred
by
Incara
Development. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Clayton Duncan, 51 Chairman,
Pres, CEO | $355K | $233K | Richard Reichow, 50 Exec.
VP, CFO, Treasurer and Sec. | 287K | 93K | David Ward, M.D., 54 Exec.
VP, R&D | 287K | -- | W. Bennett Love, 45 VP,
Corp. Planning/Communications | 146K | -- | John Richert, 50 VP,
Market Devel. | 142K | -- | Dollar
amounts are as of 30-Sep-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|